BACKGROUND: Autosomal dominant polycystic kidney disease (ADPKD) is the most common monogenic inherited kidney disease, affecting an estimated 600 000 individuals in Europe. The disease is characterized by age-dependent development of a multiple cysts in the kidneys, ultimately leading to end-stage renal failure and the need of renal replacement therapy in the majority of patients, typically by the fifth or sixth decade of life. The variable disease course, even within the same family, remains largely unexplained. Similarly, assessing disease severity and prognosis in an individual with ADPKD remains difficult. Epidemiological studies are limited due to the fragmentation of ADPKD research in Europe. METHODS: The EuroCYST initiative aims: (i) to harmonize and develop common standards for ADPKD research by starting a collaborative effort to build a network of ADPKD reference centres across Europe and (ii) to establish a multicentric observational cohort of ADPKD patients. This cohort will be used to study factors influencing the rate of disease progression, disease modifiers, disease stage-specific morbidity and mortality, health economic issues and to identify predictive disease progression markers. Overall, 1100 patients will be enrolled in 14 study sites across Europe. Patients will be prospectively followed for at least 3 years. Eligible patients will not have participated in a pharmaceutical clinical trial 1 year before enrollment, have clinically proven ADPKD, an estimated glomerular filtration rate (eGFR) of 30 mL/min/1.73 m(2) and above, and be able to provide written informed consent. The baseline visit will include a physical examination and collection of blood, urine and DNA for biomarker and genetic studies. In addition, all participants will be asked to complete questionnaires detailing selfreported health status, quality of life, socioeconomic status, health-care use and reproductive planning. All subjects will undergo annual follow-up. A magnetic resonance imaging (MRI) scan will be carried out at baseline, and patients are encouraged to undergo a second MRI at 3-year follow-up for qualitative and quantitative kidney and liver assessments. CONCLUSIONS: The ADPKD reference centre network across Europe and the observational cohort study will enable European ADPKD researchers to gain insights into the natural history, heterogeneity and associated complications of the disease as well as how it affects the lives of patients across Europe.
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across Europe and to establish a large-scale observational cohort of ADPKD patients for the 4 5 6 purpose of studying the pathogenesis, rate of disease progression, progression rate modifiers, 7 8 disease stage specific morbidity, mortality, health economic issues and the predictive value of 9 10 biomarkers in ADPKD. Overall 1,100 patients will be enrolled in 14 study sites across Europe 11 12
and will be followed up for at least three years. The ADPKD reference center network across 13 14 Europe and the observational cohort study will enable European ADPKD researchers to gain 16 17 insight into the natural history, heterogeneity and associated complications of the disease as 18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44   45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 At present there are no approved disease modifying treatments available for ADPKD.
Intensive basic research during the last three decades has contributed to a clearer understanding of the basic pathophysiological processes that lead to renal cyst formation in subjects affected by ADPKD with definition of novel therapeutic targets. 5, 6 In animal studies some of the treatments directed at these targets, such as mammalian target of rapamycin (mTOR) inhibitors, somatostatin analogues and vasopressin V 2 -receptor antagonists (V2RA), shown an effect on the rates of kidney growth and kidney function decline, although long 9 10 term treatment safety needs to be addressed. 13 Building a large, well-characterized cohort of ADPKD subjects who are followed in a 2 3
longitudinal observational cohort study has the potential to identify progression factors and 4 5 6
biomarkers, and to assess disease stage specific mortality, morbidity and health care costs. collaborative and educational liaisons as well as provide standard criteria for effective management protocols in ADPKD. The primary objectives of the EuroCYST Initiative are to: 10 11 12 13
• Build a network of ADPKD reference centers across Europe to provide a translational 14 15 research platform that will enable EU researchers to study the pathogenesis, progression with other research groups to share data and biomaterials in order to achieve maximum scientific output will be encouraged. To this end an open and transparent ancillary study policy has been established as part of the study protocol (Supplement S1).
A Steering Committee has been established and is meeting at least twice a year. All decisions by the Steering Committee will be approved on a 75% majority. The establishment 10 of 27 To build a cohort for a longitudinal observational study, 14 centers in 10 countries been co-opted, so that efforts do not need to focus on recruitment, but can be invested into the step, which is beyond the current funding period, the cohort could be extended in four ways: number of patients up to 5,000 or more through the participation of additional European study Patients who meet the inclusion criteria will be invited to participate. All potential participants will receive detailed information about the study both verbally and in writing.
Local ethical committees will approve the study and the protocol has to fulfill the local regulatory requirements and complies with Good Clinical Practice Guidelines (GCP).
The study design is shown in Figure 2 . At baseline a detailed medical and ADPKDspecific assessment will be performed. Family history/pedigree information will be collected, Eligibility of cohort participants 11 12 13
Following a consecutive enrollment approach all patients with ADPKD are considered 14 15
as potentially eligible for the study at pre-screening and will undergo screening for the study. activities of daily living. The protocol will also require a physical examination. analyses as well as completing the aforementioned ADPKD related questionnaires.
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Participating patients will be treated according to current standards of care in routine clinical a daily back up will be performed. The study data are saved on a separate server at the University Hospital Zurich, where the clinical trial center, provider of the data management system, is located. Server access is controlled physically and electronically. Each patient will be pseudo-anonymized in a reversible manner and all data introduced into the data management system is coded. Subject identification will only be possible at the local study site. Access to the system will be role specific and will only be possible with a unique User-13 of 27 The collection of material for biobanking will be conducted at the baseline visit. A 5 6 7
Standard Operating Procedure (SOP) harmonizes the procedure for sampling, pre-processing 8 9
and storage of biobanking material within the EuroCYST Initiative. Serum, plasma and whole 10 11 blood collected on EDTA and spot and 24 h urines will be collected, processed and aliquoted.
13
They will be shipped in batches to a central biobank storage facility where an automated -14 15
80°C sample library management system is in place to handle the de-identified 2D bar coded for DNA extraction and storage. The database will be kept separately with a secure method to 21 22
link clinical information to biological samples. Management Practices (GCDMP). All electronic case report forms (eCRF) have been 42 43 implemented into this system. Figure 3 shows the different subject areas of the data bank that 44 45 are reflected in the eCRF. Data will be stored for at least 10 years after study termination and 49  50  51  52  53  54  55  56  57  58  59  60 disease progression rate as assessed by the change in eGFR rate and total kidney volume (TKV) despite restrictive inclusion and exclusion criteria. Therefore a larger sample size is required to account for the broader range in age and renal function in our cohort. A mixed effects regression model will be used as the modeling framework, with a random effect for each patient (this allows correlation between repeated eGFR or TKV measurements in the 14 of 27 15 1 ID and password. High data quality will be ensured by performing regular monitoring and 2 3 reporting of entered data by the coordination center Zurich. All study site data entered in the 4 5 6 eCRF will be checked for completeness and plausibility according to predefined rules to draw 7 8 attention to missing data or errors. Certified personnel will monitor the participating center 9 10 annually. All patients' written informed consent forms and all study files will be checked for 11 12 completeness, and remain at the individual sites. In 10% of locally enrolled patients, the 13 14 source files and eCRFs will be checked for accuracy. In addition, frequent communications 16 17 and annual meetings of reference center principal investigators will ensure study compliance.
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The center's individual results of the study shall be owned by the center. Each center will 20 21 provide copies of all results, including but not limited to case report forms, to the study Formal sample size estimation has not been performed for this study. While chronic 36 37 kidney disease cohorts currently aim to enroll at least 3,000 and up to 5,000 patients (CRIC, The primary outcome measure of the study will be disease progression, assessed as The study started enrolling patients in July 2013 and will run for 36 months .   35  36  37  38  39  40  41  42  43  44  45  46  49  50  51  52  53  54  55  56  57  58  59  60 EDTA Working Group on Inherited Kidney Disorders demonstrates the interest and need for a consolidated pan-European approach in the field of inherited kidney diseases at large. 30 The establishment of such a cohort has the potential to strengthen European ADPKD investigators by harmonizing and standardizing research efforts and will guarantee that current and upcoming technologies to study chronic kidney disease can be applied to ADPKD 16 of 27 This study is supported by a grant of the ERA-EDTA. The authors declare no conflict of interest .   18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45   46  47  48  49  50  51  52  53  54  55  56  57  58  59 Appendix.
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EuroCYST study sites and Principal Investigators In response to the reviewers' opinion we modified the paragraph into "…Results of smaller 50 observational studies in ADPKD cohorts, like CRISP and SUISSE ADPKD, suggest that changes in total 51 kidney volume are a predictor of subsequent loss of kidney function. 18 …" 53 54 4. Line 17-21 of page 9: it is stated that the group acts independent from industry; however, the 55 majority of authors of this paper clearly have ties with industry, and have participated in an 56 industry sponsored RCT on this topic, and many of them probably receive industry money for 57 their research; it is therefore strange that only one conflict of interest is declared. This is not 58 really credible. The present research project is academic, independent of industry and solely funded by the ERA-EDTA.
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All authors declare no conflict of interest. The COI form of the lead author will be submitted.
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4.1 In the same line: it is stated that 14 centres will participate: how were these centres
We propose consecutive enrollment of study subjects. Consecutive enrollment is a measure to prevent 48 selection bias and we think that consecutive enrollment is important since observational studies are 49 always compromised for selection bias that subsequently can't be addressed by any statistical 50 51 approaches. Following a consecutive enrollment approach means that all ADPKD patients are 52 considered as potentially eligible for the study at pre-screening and will undergo screening for 53
EuroCYST. The screening process starts with the signature of the IC. All patients that fulfill our defined 54 inclusion criteria, do not fulfill any of the exclusion criteria and provided written informed consent are 55 considered for enrollment. Those who do not meet all the inclusion or do meet one or more of the 56 exclusion criteria will be considered as screening failures and will not be enrolled in the study. For 57 reducing the risk of a sampling bias, we propose the following approach: A stratification per study center 58 of at least 40% of enrolled patients with eGFR greater or equal than 60 ml/min*1.73m 2 .
